Chad Messer
Stock Analyst at Lake Street
(1.29)
# 3,730
Out of 4,630 analysts
500
Total ratings
37.4%
Success rate
-0.2%
Average return
Main Sectors:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEN Compugen | Reiterated: Buy | $5 → $6 | $2.41 | +148.96% | 4 | Jul 21, 2026 | |
| OSTX OS Therapies | Maintained: Buy | $13 | $1.60 | +712.50% | 19 | Jul 7, 2026 | |
| CNSY Cerenome | Reiterated: Buy | $50 | $3.83 | +1,205.48% | 6 | Jul 1, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $103 | $119.21 | -13.60% | 7 | Jun 30, 2026 | |
| GNLX Genelux | Maintained: Buy | $16 | $2.66 | +501.50% | 6 | Jun 30, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $32 | $13.89 | +130.46% | 1 | Jun 11, 2026 | |
| ONCY Oncolytics Biotech | Maintained: Buy | $5 | $0.8025 | +523.05% | 18 | Jun 1, 2026 | |
| IMNM Immunome | Maintained: Buy | $30 | $25.03 | +19.86% | 9 | Jun 1, 2026 | |
| COYA Coya Therapeutics | Maintained: Buy | $17 | $4.81 | +253.43% | 14 | May 22, 2026 | |
| LTRN Lantern Pharma | Maintained: Buy | $25 | $2.86 | +774.13% | 13 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $4.05 | +1,751.85% | 6 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.21 | - | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $7 | $8.85 | n/a | 18 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 340.00 → kr 380.00 | kr 177.10 | n/a | 13 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $1.48 | n/a | 17 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $7.44 | n/a | 7 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 | $7.27 | n/a | 5 | Aug 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.0001 | n/a | 11 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 | $92.78 | n/a | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $76.76 | n/a | 31 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $5.84 | n/a | 13 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.9099 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $104.91 | n/a | 19 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $21 | $2.11 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $45.03 | n/a | 25 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $84 | $56.56 | n/a | 50 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $6 | $0.000001 | n/a | 17 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $25.53 | n/a | 6 | Jul 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 → $30 | $54.07 | n/a | 22 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 → $83 | $1.75 | n/a | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $166 | $16.78 | n/a | 50 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.2963 | n/a | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $32.27 | n/a | 21 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.76 | n/a | 3 | Nov 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $27 | $13.96 | n/a | 3 | Apr 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $33 | $6.65 | n/a | 10 | Dec 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $0.0001 | n/a | 5 | May 7, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $12.01 | n/a | 6 | Mar 6, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.28 | n/a | 1 | Jan 5, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.82 | n/a | 1 | May 22, 2012 |
Compugen
Jul 21, 2026
Reiterated: Buy
Price Target: $5 → $6
Current: $2.41
Upside: +148.96%
OS Therapies
Jul 7, 2026
Maintained: Buy
Price Target: $13
Current: $1.60
Upside: +712.50%
Cerenome
Jul 1, 2026
Reiterated: Buy
Price Target: $50
Current: $3.83
Upside: +1,205.48%
Monopar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $103
Current: $119.21
Upside: -13.60%
Genelux
Jun 30, 2026
Maintained: Buy
Price Target: $16
Current: $2.66
Upside: +501.50%
Kazia Therapeutics
Jun 11, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $13.89
Upside: +130.46%
Oncolytics Biotech
Jun 1, 2026
Maintained: Buy
Price Target: $5
Current: $0.8025
Upside: +523.05%
Immunome
Jun 1, 2026
Maintained: Buy
Price Target: $30
Current: $25.03
Upside: +19.86%
Coya Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $17
Current: $4.81
Upside: +253.43%
Lantern Pharma
May 18, 2026
Maintained: Buy
Price Target: $25
Current: $2.86
Upside: +774.13%
May 13, 2026
Maintained: Buy
Price Target: $75
Current: $4.05
Upside: +1,751.85%
Apr 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.21
Upside: -
Nov 1, 2021
Maintained: Buy
Price Target: $6 → $7
Current: $8.85
Upside: n/a
Sep 1, 2021
Reiterated: Buy
Price Target: kr 340.00 → kr 380.00
Current: kr 177.10
Upside: n/a
Aug 17, 2021
Rated: Buy
Price Target: $3
Current: $1.48
Upside: n/a
Aug 13, 2021
Maintained: Buy
Price Target: $29
Current: $7.44
Upside: n/a
Aug 12, 2021
Maintained: Buy
Price Target: $49
Current: $7.27
Upside: n/a
Aug 10, 2021
Maintained: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Aug 10, 2021
Rated: Buy
Price Target: $50
Current: $92.78
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $48
Current: $76.76
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $30
Current: $5.84
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $10
Current: $0.9099
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $12
Current: $104.91
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $21
Current: $2.11
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $45.03
Upside: n/a
Aug 4, 2021
Rated: Buy
Price Target: $84
Current: $56.56
Upside: n/a
Jul 29, 2021
Rated: Buy
Price Target: $6
Current: $0.000001
Upside: n/a
Jul 15, 2021
Rated: Buy
Price Target: $48
Current: $25.53
Upside: n/a
Jun 28, 2021
Maintained: Buy
Price Target: $33 → $30
Current: $54.07
Upside: n/a
Jun 7, 2021
Reiterated: Buy
Price Target: $75 → $83
Current: $1.75
Upside: n/a
May 18, 2021
Reiterated: Buy
Price Target: $166
Current: $16.78
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $10
Current: $0.2963
Upside: n/a
May 10, 2021
Rated: Hold
Price Target: n/a
Current: $32.27
Upside: n/a
Nov 8, 2019
Rated: Hold
Price Target: n/a
Current: $4.76
Upside: n/a
Apr 12, 2018
Maintained: Buy
Price Target: $30 → $27
Current: $13.96
Upside: n/a
Dec 9, 2016
Reiterated: Buy
Price Target: $6 → $33
Current: $6.65
Upside: n/a
May 7, 2015
Reiterated: Buy
Price Target: $10 → $7
Current: $0.0001
Upside: n/a
Mar 6, 2015
Maintained: Buy
Price Target: $7 → $4
Current: $12.01
Upside: n/a
Jan 5, 2015
Initiated Coverage: Buy
Price Target: $17
Current: $1.28
Upside: n/a
May 22, 2012
Initiated Coverage: Buy
Price Target: $5
Current: $1.82
Upside: n/a